S&P rates Amgen notes A+

Standard & Poor's said it assigned its A+ rating to Amgen Inc.'s announced offering of senior unsecured notes to be divided into 10-year and 30-year tranches due 2019 and 2039, respectively.

The agency said it expects the proceeds to be used mainly to refinance debt.

The long-term corporate credit rating on Amgen is A+ and the outlook is stable, S&P said, adding that the A+ rating reflects the strength of the company's high-margin product portfolio and conservative financial policies, offset by its still relatively narrow drug portfolio.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.